Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | FABP6 | P51161 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626799 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL17780215 | 0.94 | ALDH1A1 (0.53) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL962569 | 0.88 | TP53 (0.43) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL12225575 | 0.88 | TP53 (0.43) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL962299 | 0.88 | TP53 (0.43) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL17780281 | 0.85 | FABP6 (0.54) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL14037777 | 0.83 | EPHX2 (0.41) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL3675986 | 0.83 | KMT2A (0.47) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL13741699 | 0.81 | TSHR (0.54) | ALDH1A1TSHRFABP6MAPK1LMNA | |
| SCHEMBL21843867 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TSHRFABP6MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| EP-2814828-B9 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | RES TRIANGLE INST (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-9458160-B2 | Peripherally restricted diphenyl purine derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160046630-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | RES TRIANGLE INST (US) | 2016-02-18 | — | — | US | disclosed |
| US-9187480-B2 | Peripherally restricted diphenyl purine derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150031689-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-29 | — | — | US | disclosed |
| EP-1871772-B1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20050113395-A1 | Method of treatment of atherosclerosis | PFIZER INC | 2005-05-26 | — | — | US | disclosed |
| US-20040116449-A1 | Method of treatment of transplant rejection | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| WO-2004047843-A1 | METHOD OF TREATMENT OF TRANSPLANT REJECTION | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040053947-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1382339-A1 | Compositions containing pyrrolo [2,3-d] pyrimidine derivatives | Pfizer Products Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1235830-B1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS | PFIZER PROD INC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6627754-B2 | Immunosuppressants; organ transplant; CP 690550 which is 3-(4-Methyl-3-(methyl-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-3-oxo-propionitrile | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1235830-A2 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20010053782-A1 | Immunosuppressants; organ transplant | BLUMENKOPF TODD A (US) | 2001-12-20 | — | — | US | disclosed |
| WO-2001042246-A2 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ALDH1A1 1767/4885TSHR 844/4885FABP6 1591/4885 |
| US-20040053947-A1 | Pyrrolo[2,3-D]pyrimidine compounds | JAK1, JAK3, TPMT | ALDH1A1 1564/4885TSHR 37/4885FABP6 2903/4885 |
| US-20150031689-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | CNR1, CNR2, P2RY1 | ALDH1A1 1149/4885TSHR 2122/4885FABP6 177/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ALDH1A1 1767/4885TSHR 844/4885FABP6 1591/4885 |
| US-20010053782-A1 | Immunosuppressants; organ transplant | JAK1, JAK3, TPMT | ALDH1A1 1606/4885TSHR 16/4885FABP6 1970/4885 |
| US-20050113395-A1 | Method of treatment of atherosclerosis | LDLR, MSR1, NR1H2 | ALDH1A1 1166/4885TSHR 1383/4885FABP6 1122/4885 |
| US-20160046630-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | CNR1, CNR2, P2RY1 | ALDH1A1 1149/4885TSHR 2122/4885FABP6 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.